SignaBlok presented preclinical data on the use of ligand-independent TREM-1 blockers as innate immune checkpoint inhibitors to overcome cancer immunotherapy resistance at the CICON23
SignaBlok attended the COVID-19 Virtual Partnering event and presented company’s approach to treatment of acute respiratory distress syndrome (ARDS), a major complication in severe cases of COVID-19
SignaBlok pitched on company’s standalone and combination immuno-oncology therapy at the 2019 Life Sciences Summit
SignaBlok selected as a RESI Pitch Challenge finalist to pitch on company’s oncology program at the 2019 Redefining Early Stage Investments (RESI) Conference
SignaBlok presented data on preclinical antitumor activity of a first-in-class TREM-1 inhibitory peptide GF9 as monotherapy and in combo with chemotherapy or radiation at the 2019 AACR Annual Meeting
SignaBlok presented preclinical data supporting efficacy of ligand-independent TREM-1 inhibitor in ameliorating alcoholic liver disease at the Liver Meeting 2018: American Association for the Study of Liver Diseases (AASLD)
SignaBlok presented its concept of nature-inspired rational design of macrophage-targeted imaging and drug delivery system for detection and treatment of inflammation at the 2018 World Molecular Imaging Congress
SignaBlok presented preclinical data on efficacy of ultra high sensitivity MRI contrast agent for diagnostic imaging of atherosclerosis in a non-rodent animal model at the 2017 World Molecular Imaging Congress
SignaBlok presented proof-of-concept animal data on development of a novel targeted treatment for retinopathy of prematurity at the 2017 ARVO Annual Meeting
SignaBlok presented preclinical data on further development of a novel ligand-independent inhibitor of TREM-1 for treatment of lung and pancreatic cancer at the 2017 AACR Annual Meeting
